Cargando…

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma

In this study, EGFR-activating mutation status and DNA copy number abundances of members of ErbB family were measured in 261 lung adenocarcinomas. The associations between DNA copy number abundances of ErbB family, EGFR-activating mutation status, and prognosis were explored. Results showed that DNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hsuan-Yu, Liu, Chia-Hsin, Chang, Ya-Hsuan, Yu, Sung-Liang, Ho, Bing-Ching, Hsu, Chung-Ping, Yang, Tsung-Ying, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Hsia, Jiun-Yi, Chuang, Cheng-Yen, Chang, Chi-Sheng, Li, Yu-Cheng, Li, Ker-Chau, Chang, Gee-Chen, Yang, Pan-Chyr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891022/ https://www.ncbi.nlm.nih.gov/pubmed/26824984 http://dx.doi.org/10.18632/oncotarget.7029

Ejemplares similares

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

Tumor mutation burden and recurrent tumors in hereditary lung cancer
por: Hsu, Yi‐Chiung, et al.
Publicado: (2019)

Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma
por: Raghav, Lovely, et al.
Publicado: (2020)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
por: Su, Sheng-Fang, et al.
Publicado: (2021)

Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2016)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma
por: Chang, Ya-Hsuan, et al.
Publicado: (2015)

Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
por: Ou, Wei-Fan, et al.
Publicado: (2023)

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2015)

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity
por: Hsu, Yi-Chiung, et al.
Publicado: (2013)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2022)

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018
por: Tseng, Jeng-Sen, et al.
Publicado: (2022)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
por: Lee, Po-Hsin, et al.
Publicado: (2021)

ePIANNO: ePIgenomics ANNOtation tool
por: Liu, Chia-Hsin, et al.
Publicado: (2016)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2020)

Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients
por: Liu, Rui, et al.
Publicado: (2017)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma
por: Andolfo, Immacolata, et al.
Publicado: (2011)

Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma
por: Jones, DeAnalisa C., et al.
Publicado: (2018)

Neuregulin Facilitates Nerve Regeneration by Speeding Schwann Cell Migration via ErbB2/3-Dependent FAK Pathway
por: Chang, Hung-Ming, et al.
Publicado: (2013)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_qdv9fna06m5tjmc60fh8si2nsu